Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: 45 Years to 85 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Isolated Systolic Hypertension, Endothelial Dysfunction
Interventions: 6R-BH4, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions: Not listed
Lead sponsor: Global Healthy Living Foundation; Other
Eligibility: 19 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Upper Nyack, New York

Conditions: Hypertension, Grade 1, Hypertension Treatment, N of 1 Study Design, Hypertension
Interventions: Lisinopril, Hydrochlorothiazide; Drug
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypertension
Interventions: Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg); Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more

Conditions: Diabetes, Hypertension
Interventions: Reminder, Fresh start, Fresh start framing; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 13,323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: CHW Education, CHW Education and Navigation; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 69 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypertension
Interventions: Nebivolol, Hydrochlorothiazide; Drug
Lead sponsor: InVasc Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Diabetes
Interventions: carvedilol, metoprolol; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 45 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Diabetes, Hypertension, Dyslipidemia, Coronary Arteriosclerosis
Interventions: Behavioral counseling and peer support, Interactive Education, Role modeling, Pharmacologic case management; Behavioral · Procedure
Lead sponsor: Providence VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Pulmonary Hypertension
Interventions: Use of Eko DUO stethoscope (paired ECG/PCG); Device
Lead sponsor: Eko Devices, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Providence, Rhode Island

Conditions: Hypertension, High Blood Pressure
Interventions: Not listed
Lead sponsor: Ouraring Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 382,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Depression, Hypertension
Interventions: Mindfulness-Based Stress Reduction (MBSR; CALM-Chicago Study); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Partial sleep deprivation (sleep restriction), Normal sleep; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 35 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: David Grant U.S. Air Force Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Travis Air Force Base, California

Conditions: Hypertension, Elevated Blood Pressure
Interventions: Vascanox® HP; Dietary Supplement
Lead sponsor: Calroy Health Sciences; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension (HTN)
Interventions: Firibastat (QGC001) Period 1; Drug
Lead sponsor: Quantum Genomics SA; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Manassas, Virginia

Conditions: Diabetes, Hypertension, Obesity
Interventions: Intralipid 20%, Normal Saline, Oral fat load; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Obesity
Interventions: Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan, Standard-of-care; Drug · Other
Lead sponsor: Actelion; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Glaucoma
Interventions: P200TE, P200TxE; Device
Lead sponsor: Optos, PLC; Industry
Eligibility: 22 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Does the Optic Disc Grading Done Visually by Your Doctor Agree With Optic Nerve Testing Which is Done by Machines?

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

PatientSpot Formerly Known as ArthritisPower

Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril

Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

Fresh Start Experiment

Improving Blood Pressure Control Among Food Insecure Hypertensive Adults

Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension

Comparison of Blood Pressure Medications on Metabolism

Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients

Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope

Oura Blood Pressure Profile Study

Community-based Approach to Lowering Stress Through Mindfulness

Sleep Restriction and Parental History of Hypertension

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus

Open Label Clinical Trial of Vascanox® HP on Nitric Oxide and Blood Pressure

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

FFA Hypertension and Inflammation in Lean and Obese Subjects

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients

Study Comparing the P200TE and the P200TxE in Glaucoma Patients